Xbrane Biopharma: Positive CHMP Opinion - Redeye

Redeye feels encouraged following today’s positive CHMP opinion on Ximluci (Xlucane), marking a major milestone for the company and its partner STADA. Today’s news further de-risks the investment case, and we continue to see an upside opportunity in Xbrane shares.

Länk till analysen i sin helhet: https://www.redeye.se/research/855723/xbrane-biopharma-positive-chmp-opinion?utm_source=finwire&utm_medium=RSS